Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02512172 · ClinicalTrials.gov registry record · Phase 1
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02512172 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 27 participants.
The verdict
NCT02512172, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study is being done to test the safety and effectiveness of the combination of intravenous (IV) romidepsin and/or oral 5-azacitidine with IV MK-3475 in people with microsatellite stable (MSS) advanced colorectal cancer.
Interventions
- DRUG Romidepsin
- DRUG MK-3475
- DRUG Oral CC-486
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-02-19 |
| Est. Completion | 2021-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02512172
The ClinicalTrials.gov registry entry for NCT02512172 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Romidepsin is the first listed.
NCT02512172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02512172 about?
NCT02512172 is a clinical study titled "A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer". This study is being done to test the safety and effectiveness of the combination of intravenous (IV) romidepsin and/or oral 5-azacitidine with IV MK-3475 in people with microsatellite stable (MSS) advanced colorectal cancer.
What is the current status of trial NCT02512172?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2016-02-19. Estimated completion is 2021-11-20.
What interventions are being tested in trial NCT02512172?
The interventions under investigation include: Romidepsin (DRUG), MK-3475 (DRUG), Oral CC-486 (DRUG).
Who is sponsoring clinical trial NCT02512172?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.